共 50 条
- [1] Phase II Trial of Lenalidomide in Patients with Relapsed or Refractory Hodgkin LymphomaBLOOD, 2008, 112 (11) : 1049 - 1049Kuruvilla, JohnTaylor, DianeWang, LisaBlattler, ChantaleKeating, ArmandCrump, Michael
- [2] Safety and effectiveness of lenalidomide in Japanese patients with relapsed/refractory ATLL: post-marketing surveillanceInternational Journal of Hematology, 2025, 121 (1) : 79 - 88Tohru MiyazakiShuji UnoHiroaki FujimoriYoko Motegi
- [3] Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) : 584 - 591Badoux, Xavier C.Keating, Michael J.Wen, SijinWierda, William G.O'Brien, Susan M.Faderl, StefanSargent, RachelBurger, Jan A.Ferrajoli, Alessandra
- [4] Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II studyJOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) : 5343 - 5349Chanan-Khan, AsherMiller, Kena C.Musial, LaurieLawrence, DavidPadmanabhan, SwaminathanTakeshita, KenichiPorter, Carl W.Goodrich, David W.Bernstein, Zale P.Wallace, PaulSpaner, DavidMohr, AliceByrne, CatrionaHernandez-Ilizaliturri, FranciscoChrystal, CynthiaStarostik, PetrCzuczman, Myron S.
- [5] The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II studyBRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (03) : 326 - 333Schey, Stephen A.Morgan, Gareth J.Ramasamy, KarthikHazel, BethLadon, DariuszCorderoy, SophieJenner, MatthewPhekoo, KarenBoyd, KevinDavies, Faith E.
- [6] Phase II Study of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309BLOOD, 2016, 128 (22)Kline, JustinRapoport, Aaron P.Petrich, Adam M.Cohen, Kenneth S.Thomas, Sachdev P.Nattam, SreenivasaRao, KrishnaSleckman, BethanyStadler, WalterKarrison, TheodoreSmith, Sonali M.
- [7] A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBLOOD, 2006, 108 (10) : 3458 - 3464Richardson, Paul G.Blood, EmilyMitsiades, Constantine S.Jagannath, SundarZeldenrust, Steven R.Alsina, MelissaSchlossman, Robert L.Rajkumar, S. VincentDesikan, K. RamanHideshima, TeruMunshi, Nikhil C.Kelly-Colson, KathleenDoss, DeborahMcKenney, Mary L.Gorelik, SvetlanaWarren, DianeFreeman, AndreaRich, RebeccaWu, AnfangOlesnyckyj, MartaWride, KentonDalton, William S.Zeldis, JeromeKnight, RobertWeller, EdieAnderson, Kenneth C.
- [8] Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory LymphomasBLOOD, 2020, 136Major, AjayKline, JustinKarrison, Theodore G.Fishkin, Paul A. S.Kimball, Amy S.Petrich, Adam M.Nattam, SreenivasaSleckman, Bethany G.Cohen, Kennethvan Besien, KoenRapoport, Aaron P.Smith, Sonali M.
- [9] Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomasHAEMATOLOGICA, 2022, 107 (07) : 1608 - 1618Major, AjayKline, JustinKarrison, Theodore G.Fishkin, Paul A. S.Kimball, Amy S.Petrich, Adam M.Nattam, SreenivasaRao, KrishnaSleckman, Bethany G.Cohen, Kennethvan Besien, KoenRapoport, Aaron P.Smith, Sonali M.
- [10] Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemiaLEUKEMIA RESEARCH, 2016, 47 : 78 - 83Chavez, Julio C.Piris-Villaespesa, MiguelDalia, SamirPowers, JohnTurba, ElyceNodzon, LisaKomrokji, RamiSokol, LubomirLocke, Frederick L.Lancet, JeffreySotomayor, Eduardo M.Kharfan-Dabaja, Mohamed A.Pinilla-Ibarz, Javier